Suvemcitug clinical trials
Also written Sevacizumab and BD0801.
How each study uses suvemcitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the suvemcitug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2026 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 4
Jiangsu Simcere Pharmaceutical Co., Ltd. (6) · Tongji Hospital (1) · Anhui Provincial Hospital (1) · Fudan University (1) · Peking University Third Hospital (1)
Often tested with
Tested in the same studies.
Mirvetuximab soravtansine (2) · Modified FOLFOX6 Regimen (1) · Enlonstobart (1) · Trifluridine (1) · Tipiracil (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test suvemcitug.
- Jun 2027Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerPhase 2 · Peking University Third Hospital
Studies
Open first, then newest update. How each study uses suvemcitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNot yet recruitingPhase 2Tongji HospitalNCT07934121Written as Suvemcitug
- Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian CancerNot yet recruitingPhase 2Anhui Provincial HospitalNCT07920159Written as Suvemcitug
- Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07810114Written as Suvemcitug
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Third HospitalNCT07741630Written as Suvemcitug
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07361003Written as Suvemcitug injection, trifluridine/tipiracil tablets
- A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerCompletedPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT04908787Written as BD0801
- A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid TumorsTerminatedPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05148195Written as BD0801
- A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Status unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT03763123Written as Sevacizumab
- A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal CancerStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT02453464Written as Sevacizumab
- A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid TumorsStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01847118Written as Sevacizumab
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNov 12, 2026NCT07934121
- Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian CancerNov 5, 2026NCT07920159
Codes
What other systems call suvemcitug · ClinicalTrials.gg INT017995
- UNII (FDA) T7Y5VC4ERJSUVEMCITUGOne source FDA
- NCI Thesaurus C122403SuvemcitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T7Y5VC4ERJ | SUVEMCITUG | One source FDA |
| NCI Thesaurus | C122403 | Suvemcitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.